Diamyd Medical AB Class B DYMDF
Trading Information
- Previous Close Price
- —
- Day Range
- $0.73–0.73
- 52-Week Range
- $0.73–0.73
- Bid/Ask
- — / —
- Shares Outstanding
- 154.98M
- Market Cap
- $100.37M
- Volume/Avg
- 39,121 / 39,121
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6,070.29
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 45
- Website
- https://www.diamyd.com
Valuation
|
Metric
|
DYMDF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.95 |
Price/Sales | 6,070.29 |
Price/Cash Flow | — |
Price/Earnings
DYMDF
Financial Strength
|
Metric
|
DYMDF
|
|---|---|
Quick Ratio | 15.49 |
Current Ratio | 15.50 |
Interest Coverage | −177.23 |
Quick Ratio
DYMDF
Profitability
|
Metric
|
DYMDF
|
|---|---|
Return on Assets (Normalized) | −82.68% |
Return on Equity (Normalized) | −112.07% |
Return on Invested Capital (Normalized) | −113.93% |
Return on Assets
DYMDF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|zX$@<G | LOCK|%@$% | $129B | |||
| Moderna Inc
MRNA
| LOCK|^&TR>^ | LOCK|R> | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|g<Z!wl | LOCK|>>B?% | $79B | |||
| argenx SE ADR
ARGX
| LOCK|d!l$Y! | LOCK|?# | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|xsBtFWD | LOCK|?z | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|BQ@mk> | LOCK|Vj<Dy | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<BrK&W<< | LOCK|XX>Tt | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|QP!?FV | LOCK|Hbp | $24B | |||
| Incyte Corp
INCY
| LOCK|nPpz@$ | LOCK|^G | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>z&!>$$ | LOCK|gSh | $14B |
United States